切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2019, Vol. 13 ›› Issue (07) : 540 -543. doi: 10.3877/cma.j.issn.1674-0785.2019.07.012

所属专题: 文献

综述

结直肠癌肝转移局部治疗的研究进展
敬聪1, 任勇军1,(), 邓进1, 闵旭立1, 徐浩1, 陈智粮1   
  1. 1. 637000 四川南充,川北医学院附属医院介入放射科,四川省医学影像重点实验室
  • 收稿日期:2019-02-13 出版日期:2019-04-01
  • 通信作者: 任勇军
  • 基金资助:
    四川省教育厅自然类科研基金(17ZB0169); 南充市科技局自然类科研基金(16YFZJ0054)

Progress in local treatment of liver metastasis of colorectal cancer

Cong Jing1, Yongjun Ren1,(), Jin Deng1, Xuli Min1, Hao Xu1, Zhiliang Chen1   

  1. 1. Department of Interventional Radiology, Sichuan Key Laboratory of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan, China
  • Received:2019-02-13 Published:2019-04-01
  • Corresponding author: Yongjun Ren
  • About author:
    Corresponding author: Ren Yongjun, Email:
引用本文:

敬聪, 任勇军, 邓进, 闵旭立, 徐浩, 陈智粮. 结直肠癌肝转移局部治疗的研究进展[J]. 中华临床医师杂志(电子版), 2019, 13(07): 540-543.

Cong Jing, Yongjun Ren, Jin Deng, Xuli Min, Hao Xu, Zhiliang Chen. Progress in local treatment of liver metastasis of colorectal cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2019, 13(07): 540-543.

结直肠癌是常见的消化道恶性肿瘤,易发生肝转移。外科手术切除肝转移病灶是重要治疗方法之一。随着临床诊疗技术的进步,介入治疗、放射治疗等方法已成为结直肠癌肝转移的重要治疗手段。本文将对结直肠癌肝转移局部治疗的研究进展进行综述。

Colorectal cancer is a common gastrointestinal malignancy, which is prone to liver metastasis. Surgical resection of liver metastases is one of the important treatment methods. With the progress of clinical diagnosis and treatment technology, interventional therapy, radiotherapy, and other methods have become important options of treatment for colorectal cancer liver metastasis. This article will review the progress in local treatment of liver metastasis of colorectal cancer.

[1]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer, 2015, 136: E359-E386.
[2]
Brenner H, Kloor M, Pox CP. Colorectal cancer [J]. Lancet, 2014, 383(9927): 1490-1502.
[3]
Levy J, Zuckerman J, Garfinkle R, et al. Hepatic intra-arterial therapies for unresectable and chemo-refractory colorectal cancer liver metastases: systematic review and pooled analysis [J]. HPB, 2017, 19(1): S53.
[4]
Tomlinson JS, Jarnagin WR, DeMatteo RP. Actual 10-year survival after resection of colorectal liver metastases defines cure [J]. J Clin Oncol, 2007, 25(29): 4575-4580.
[5]
House MG, Kemeny NE, Gönen M. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer [J]. Ann Surg, 2011, 254(6): 851-856.
[6]
Sharma S, Camci C, Jabbour N. Management of hepatic metastasis from color ectal cancers: an update [J]. J Hepatobiliary Pancreat Surg, 2008, 15(6): 570-580.
[7]
Norén A, Eriksson HG, Olsson LI. Selection for surgery and survival of synchronous colorectal liver metastases, a nationwide study [J]. Eur J Cancer, 2016, 53: 105-114.
[8]
Norén A, Sandstrom P, Gunnarsdottir K, et al. Identification of inequalities in the selection of liver surgery for colorectal liver metastase in Sweden [J]. Scand J Surg, 2018, 4(107): 294-301.
[9]
Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: Current status [J]. World J Radiol, 2010, 2(11): 417-424.
[10]
Gillams A, Goldberg N, Ahmed M, et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013 [J]. Eur Radiol, 2015, 25(12): 3438-3454.
[11]
Cheng JQ, Weng M, Zhang Y, et al. Radiofrequency ablation versus resection for colorectal cancer liver metastases: a metaanalysis [J]. PLoS One, 2012, 7(9): e45493.
[12]
Babawale SN, Jensen TM, Frkjr JB. Long-term survival following radiofrequency ablation of colorectal liver metastases: a retrospective study [J]. World J Gastrointest Surg, 2015, 7(3): 33-38.
[13]
Sucandy I, Cheek S, Golas BJ, et al. Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors [J]. HPB( Oxford), 2016, 18(9): 756-763.
[14]
Lee BC, Lee HG, Park IJ, et al. The role of radiofrequency ablation for treatment of metachronous isolated hepatic metastasis from colorectal cancer [J]. Medicine (Baltimore), 2016, 95( 39): e4999.
[15]
Zarour LR, Anand S, Billingsley KG, et al. Colorectal cancer liver metastasis: evolving paradigms and future directions [J]. Cell Mol Gastroenterol Hepatol, 2017, 3(2): 163-173.
[16]
Stang A, Oldhafer KJ, Weilert H, et al. Selection criteria for radiofrequency ablation for colorectal liver metastases in the era of effective systemic therapy: a clinical score based proposal [J]. BMC Cancer, 2014, 14: 500.
[17]
Tombesi P, Di VF, Sartori S. Resection vs thermal ablation of small hepatocellular carcinoma: what′s the first choice? [J]. World J Radiol, 2013, 5(1): 1-4.
[18]
Shono Y, Tabuse K, Tsuji T, et al. Microwave coagulation therapy for unresectable colorectal metastatic liver tumor [J]. Gan To Kagaku Ryoho, 2002, 29(6): 856-859.
[19]
Grundmann RT, Hermanek P, Merkel S, et al. Diagnosis and treatmen t of colorectal liver metastases workflow [J]. Zentralbl Chir, 2008, 133(3): 267-284.
[20]
Correa-Gallego C, Fong Y, Gonen M, et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases [J]. Ann Surg Oncol, 2014, 21(13): 4278-4283.
[21]
Song KD. Percutaneous cryoablation for hepatocellular carcinoma [J]. Clin Mol Hepatol, 2016, 22(4): 509-515..
[22]
Wang C, Wang H, Yang W, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma [J]. Hepatology, 2015, 61(5): 1579-1590.
[23]
Rong G, Bai W, Dong Z, et al. Longterm outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria [J]. PloS One, 2015, 10(4): e0123065.
[24]
Huppert P, Wenzel T, Wietholtz H. Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population [J]. Cardiovasc Intervent Radiol, 2014, 37(1): 154-164.
[25]
Breedis C, Young G. The blood supply of neoplasms in the liver [J]. Am J Pathol, 1954, 30(5): 969-977.
[26]
含笑. 肝转移癌TACE疗效评价及影响因素分析[D].合肥:安徽医科大学, 2013.
[27]
Li C, Gu Y, Zhao M, et al. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer [J]. Cancer Chemother Pharmacol, 2014, 74(5): 1079-1087.
[28]
Scorsetti M, Comito T, Tozzi A, et al. Final results of a phase Ⅱ trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer [J]. J Cancer Res Clin Oncol, 2015, 141(3): 543-553.
[29]
Hoyer M, Roed H, Traberg Hansen A, et al. PhaseⅡ study on stereotactic body radiotherapy of colorectal metastases [J]. Acta Oncol, 2006, 45(7): 823-830.
[30]
van der Pool AE, Méndez Romero A, Wunderink W, et al. Stereotactic body radiation therapy for colorectal liver metastases [J]. Br J Surg, 2010, 97(3): 377-382.
[31]
Ren ZG, Zhao JD, Gu K, et al.Three-dimensional conformal radiation therapy and intensity-modulated radiation therapy combined with transcatheter arterial chemoembolization for locally advanced hepatocellular carcinoma: an irradiation dose escalation study [J]. Int J Radiat Oncol Biol Phys, 2011, 79(2): 496-502.
[32]
van Hazel GA, Heinemann V, Sharma NK, et al.SIRFLOX: randomized phase Ⅲ trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2016, 34(15): 1723-1731.
[33]
周定中, 曹苏娟, 李庆, 等. TACE联合DC-CIK生物治疗结直肠癌肝转移的临床应用 [J].临床放射学杂志, 2016, 35(5): 771-774.
[34]
翟霏霏. 树突状细胞疫苗联合射频消融术治疗结直肠癌转移临床疗效[D].合肥: 安徽医科大学, 2016.
[35]
吴倩, 张文涛, 沈健美. 高能聚焦超声刀联合化疗治疗不能手术的结直肠癌肝转移的近期疗效 [J]. 现代肿瘤医学, 2016, 24(17): 2755-2758.
[1] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[2] 代莉, 邓恢伟, 郭华静, 黄芙蓉. 术中持续输注艾司氯胺酮对腹腔镜结直肠癌手术患者术后睡眠质量的影响[J]. 中华普通外科学文献(电子版), 2023, 17(06): 408-412.
[3] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[4] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[5] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[6] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[7] 李婷, 张琳. 血清脂肪酸代谢物及维生素D水平与结直肠癌发生的关系研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 661-665.
[8] 常剑, 邱峰, 毛郁琪. 摄食抑制因子-1与腹腔镜结直肠癌根治术后肝转移的关系分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 502-505.
[9] 王晓燕, 肖佑, 肖戈, 王真权. 老年结直肠癌肺转移CT特征及高危因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 506-509.
[10] 崔佳琪, 吴迪, 陈海艳, 周惠敏, 顾元龙, 周光文, 杨军. TACE术后并发肝脓肿的临床诊治分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 688-693.
[11] 倪文凯, 齐翀, 许小丹, 周燮程, 殷庆章, 蔡元坤. 结直肠癌患者术后发生延迟性肠麻痹的影响因素分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 484-489.
[12] 范小彧, 孙司正, 鄂一民, 喻春钊. 梗阻性左半结肠癌不同手术治疗方案的选择应用[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 500-504.
[13] 关旭, 王锡山. 基于外科与免疫视角思考结直肠癌区域淋巴结处理的功与过[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 448-452.
[14] 顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
[15] 萨仁高娃, 张英霞, 邓伟, 闫诺, 樊宁. 超声引导下鼠肝消融术后组织病理特征的变化规律及影响[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 394-398.
阅读次数
全文


摘要